Inhibition of Neuronal Voltage-Gated Sodium Channels by Brilliant Blue G

Sooyeon Jo and Bruce P. Bean
Department of Neurobiology, Harvard Medical School, Boston, Massachusetts
Received December 1, 2010; accepted May 2, 2011

ABSTRACT
Brilliant blue G (BBG), best known as an antagonist of P2X7 receptors, was found to inhibit voltage-gated sodium currents in N1E-115 neuroblastoma cells. Sodium currents elicited from a holding potential of \(-60\) mV were blocked with an IC\(50\) of 2 \(\mu M\). Block was enhanced in a use-dependent manner at higher stimulation rates. The voltage-dependence of inactivation was shifted in the hyperpolarizing direction, and recovery from inactivation was slowed by BBG. The most dramatic effect of BBG was to slow recovery from inactivation after long depolarizations, with 3 \(\mu M\) BBG increasing half-time for recovery (measured at \(-120\) mV) from 24 to 854 ms after a 10-s step to 0 mV. These results were mimicked by a kinetic model in which BBG binds weakly to resting channels (\(K_d = 170 \mu M\)) but tightly to fast-inactivated channels (\(K_d = 5 \mu M\)) and even more tightly (\(K_d = 0.2 \mu M\)) to slow-inactivated channels. In contrast to BBG, the structurally related food-coloring dye Brilliant Blue FCF had very little effect at concentrations up to 30 \(\mu M\). These results show that BBG inhibits voltage-gated sodium channels at micromolar concentrations. Although BBG inhibition of sodium channels is less potent than inhibition of P2X7 receptors, there may be significant inhibition of sodium channels at BBG concentrations achieved in spinal cord or brain during experimental treatment of spinal cord injury or Huntington’s disease. Considered as a sodium channel blocker, BBG is remarkably potent, acting with more than 10-fold greater potency than lacosamide, another blocker thought to bind to slow-inactivated channels.

Introduction
The dye brilliant blue G (BBG), also known as Coomassie blue, is best known for its use in staining proteins in gel electrophoresis. However, BBG has also been recognized as a potential pharmacological agent, particularly for treating conditions involving neuronal death. Recent reports have shown that in vivo administration of BBG protects against amyloid-\(\beta\)-induced neuronal loss in a mouse model of Alzheimer’s disease (Ryu and McLarnon, 2008) and attenuates neuronal apoptosis and motor deficits in a mouse model of Huntington’s disease (Díaz-Hernández et al., 2009). It has been shown that BBG administered intravenously improves recovery and reduces local inflammatory responses in rats with spinal cord injury (Peng et al., 2009). The molecular targets of BBG are not completely understood. BBG is known to be a potent antagonist of the ATP-activated P2X7 receptor, blocking the receptor with an IC\(50\) of 10 to 200 nM (Jiang et al., 2000), with 1000-fold less potent effects on other P2X receptors. Possible effects on other types of ion channels have not been reported.

BBG is a structural derivative of FD&C blue dye number 1 (also known as brilliant blue FCF), a widely used food dye that is considered to be nontoxic (Borzelleca et al., 1990). Possible toxicity of brilliant blue FCF, however, is still somewhat controversial, and recent reports indicate that application of brilliant blue FCF with other food dyes can induce neurotoxicity and inhibit hippocampal neurogenesis (Lau et al., 2006; Park et al., 2009). Thus the effects of brilliant blue FCF on neuronal function are also of considerable interest.

Here, we present experiments showing that external BBG can inhibit neuronal tetrodotoxin-sensitive sodium channels with micromolar affinity. BBG inhibition of sodium channels seems to involve a strong interaction with both fast-inactivated and slow-inactivated sodium channels. Although BBG inhibition of sodium channels is less potent than its inhibition of the P2X7 receptor, it is the most potent agent yet described for inhibiting sodium channels by interacting with the process of slow inactivation.

Materials and Methods
Mouse Neuroblastoma N1E-115 Cell Culture. Mouse N1E-115 neuroblastoma cells were purchased from American Type Culture
Collection (Manassas, VA). Cells were grown in Dulbecco’s modified Eagle’s medium (American Type Culture Collection) containing 10% fetal bovine serum (Sigma-Aldrich, St. Louis, MO) and penicillin/streptomycin (Sigma-Aldrich) under 5% CO2 at 37°C. For electrophysiological recording, cells were grown on coverslips for 12 to 24 h after plating.

**Reverse Transcription-PCR.** Total RNA was purified from 1.5 × 10^5 N1E-115 cells using RNeasy Mini Kit (QIAGEN, Valencia, CA) and used for cDNA synthesis with random hexamers and Moloney murine leukemia virus reverse transcriptase (Promega, Madison, WI). Primer sets for each type of Na+ channel were prepared as in Gao et al. (2009). PCRs using reverse transcription reaction products were performed (94°C for 2 min; 25 cycles of 94°C for 30 s, 55°C for 30 s; and 72°C for 40 s; 72°C for 10 min).

**Electrophysiology.** Whole-cell recordings were obtained using patch pipettes with resistances of 2 to 3.5 MΩ when filled with the internal solution, consisting of 61 mM CsF, 61 mM CsCl, 9 mM NaCl, 1.8 mM MgCl2, 9 mM EGTA, 14 mM creatine phosphate (Tris salt), 4 mM magnesium-ATP, and 0.3 mM GTP (Tris salt), 9 mM HEPES, pH adjusted to 7.2 with CsOH. The shank of the electrode was wrapped with Parafilm to reduce capacitance and allow optimal series resistance compensation without oscillation. Seals were obtained and the whole-cell configuration established with cells in Tyrode’s solution (155 mM NaCl, 3.5 mM KCl, 1.5 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, and 10 mM glucose, pH adjusted to 7.4 with NaOH). To ensure complete dialysis with pipette solution, recordings began after 5 to 10 min after establishment of the whole-cell configuration. The amplifier was tuned for partial compensation of series resistance, and peak currents (Benzinger et al., 1999; Kondratiev et al., 2003; Errington et al., 2008). Cells were clamped in the whole-cell configuration, and peak current was evoked by 20-ms test pulses to 0 mV from a holding potential of −60 mV or −80 mV, which span the range of typical resting potentials of mammalian neurons. At a holding potential of −60 mV, 3 µM BBG dramatically reduced the sodium current (reduction to 44 ± 3% of control) without an obvious effect on the kinetics of the current (Fig. 1A). The inhibition was partially reversible after removal of BBG (Fig. 1B). Figure 1C shows the dose-dependence of inhibition of sodium current by BBG. The dose-response relationship for inhibition could be fit reasonably well by the equation 1/(1 + [BBG]/IC50), the relationship expected for 1:1 binding of drug to receptor, where IC50 is the half-blocking concentration. For test pulses delivered from a holding potential of −60 mV, sodium current was almost blocked completely by 30 µM BBG and the IC50 was 2.2 ± 0.3 µM (n = 3–5; Fig. 1C). When test pulses were delivered from a holding potential of −80 mV, block was significantly less potent, with an IC50 of 9.7 ± 1.3 µM (n = 3–5). The difference in blocking potency at the two different holding potentials can most easily be explained if BBG binds more tightly to the inactivated state of the sodium channel than to the closed “resting” state. At −80 mV, only approximately 10% of the channels are in the inactivated state, whereas at −60 mV, approximately 75% of the channels are in the inactivated state (Fig. 4A). As expected from this, the blocking potency was even lower (IC50 of 171 ± 1.3 µM; n = 4) with a holding potential of −120 mV, in which channels should be almost exclusively in the resting state. As will be shown, the tighter binding to inactivated channels at more depolarized holding potentials probably involves binding to distinct fast- and slow-inactivated states with different affinities.

These results show that BBG inhibits the sodium channels present in N1E-115 cells with micromolar affinity at physiological resting potentials. To determine what type of sodium channels are being targeted in these experiments, we performed reverse transcription-PCR to determine which sodium channels are expressed in N1E-115 cells. We found expression of the neuronal sodium channel Na1.3 with no detectable expression of other isoforms (Fig. 1D).

**BBG Produces Use-Dependent Block of Sodium Channels.** We next tested for possible use-dependent block of sodium channels by BBG. Under control conditions, there was relatively little change in the sodium current if the stimulation rate was abruptly increased from 0.05- to 3-Hz stimulation (current in the last pulse after 1 min of 3-Hz stimulation was 93 ± 1% compared with the first; n = 4). However, in the presence of 3 µM BBG, there was substantial use-dependent block during 3-Hz stimulation such that current in the last pulse was reduced to 65 ± 5% (n = 4) of the current elicited by the first pulse (Fig. 2). When the stimulation rate was returned to 0.05 Hz, the current slowly recovered. After 1 min of 0.05 Hz stimulation, the current in the presence of BBG recovered to 97 ± 1% of the original control current (n = 4). Recovery could be fit with an exponential time course with time constant 17 ± 6 s.

**BBG Alters Voltage-Dependence of Fast Inactivation but Not Activation.** Application of 3 µM BBG reduced the peak currents at all test potentials equally (Fig. 3, A and B). The plot of peak conductance versus test voltage could be fit fairly well by a Boltzmann function (Fig. 3C), and there was no significant difference in the voltage for half-activation in control (−28.8 ± 1.7 mV) and with 3 µM BBG (−29.1 ± 2.2 mV; n = 4, P = 0.7, paired t test).

Figure 4 shows the effect of BBG on the voltage-dependence of inactivation, determined using 1-s steps to various voltages followed by a test pulse to 0 mV to assay sodium channel availability. BBG produced a negative shift in the voltage-dependence of inactivation. The effect of BBG on inactivation was dose-dependent, with larger concentrations producing a larger hyperpolarizing shift in the midpotential (Fig. 4). However, in the presence of 3 µM BBG, there was substantial use-dependent block during 3-Hz stimulation such that current in the last pulse was reduced to 65 ± 5% (n = 4) of the current elicited by the first pulse (Fig. 2). When the stimulation rate was returned to 0.05 Hz, the current slowly recovered. After 1 min of 0.05 Hz stimulation, the current in the presence of BBG recovered to 97 ± 1% of the original control current (n = 4). Recovery could be fit with an exponential time course with time constant 17 ± 6 s.

**Results**

**BBG Inhibits Voltage-Gated Sodium Channels.** Mouse-derived N1E-115 neuroblastoma cells are a convenient preparation for studying the pharmacology of voltage-gated sodium channels because they express sizeable tetrodotoxin-sensitive sodium currents with only small potassium currents (Benzingier et al., 1999; Kondratiev et al., 2003; Errington et al., 2008). Cells were clamped in the whole-cell configuration, and peak current was evoked by 20-ms test pulses to 0 mV from a holding potential of either −60 or −80 mV, which span the range of typical resting potentials of mammalian neurons. At a holding potential of −60 mV, 3 µM BBG dramatically reduced the sodium current (reduction to 44 ± 3% of control) without an obvious effect on the kinetics of the current (Fig. 1A). The inhibition was partially reversible after removal of BBG (Fig. 1B). Figure 1C shows the
(15 ± 4% with BBG compared with 11 ± 3% in control, P = 0.02) and the slow phase had an average time constant of 7.2 ± 0.4 ms and the slow phase had an average time constant of 58 ± 11 ms (n = 4). Recovery was slower in 3 μM BBG, but not dramatically. With 3 μM BBG, the fast phase was slower (time constant of 7.2 ± 0.8 ms, P = 0.02) and the slow phase was also slower (time constant of 94 ± 16 ms, P = 0.012). The relative amplitude of the slow phase was greater with BBG (15 ± 2% with BBG compared with 11 ± 0.8% in control, P = 0.06; n = 4).

**BBG Slows Recovery from Inactivation.** Many compounds that produce a shift in the steady-state inactivation curve of sodium channels and show use-dependent potentiation of block also produce slowing of recovery from inactivation (Bean et al., 1983; Kuo et al., 1997). Accordingly, we examined the effect of BBG on the time course of recovery from inactivation. In a first series of experiments (Fig. 5A), we examined recovery at a holding potential of −80 mV after a 20-ms prepulse to 0 mV. The time course of recovery in control could be fit by the sum of two exponentials, a dominant fast phase with a time constant of approximately 5 ms and a small slow phase with a time constant of approximately 50 ms. In collected results in control, the fast phase was 89 ± 1% of the total and had a time constant of 4.9 ± 0.4 ms and the slow phase had an average time constant of 58 ± 11 ms (n = 4). Recovery was slower in 3 μM BBG, but not dramatically. With 3 μM BBG, the fast phase was slower (time constant of 7.2 ± 0.8 ms, P = 0.02) and the slow phase was also slower (time constant of 94 ± 16 ms, P = 0.012). The relative amplitude of the slow phase was greater with BBG (15 ± 2% with BBG compared with 11 ± 0.8% in control, P = 0.06; n = 4).
Figure 5B shows the effect of BBG on recovery from inactivation using a different protocol in which inactivation was induced by a much longer (10-s) depolarization to 0 mV. To avoid the complication that with a holding potential of −80 mV channels are already significantly inhibited by BBG during the first pulse to 0 mV, we used a holding potential of −120 mV, where steady-state resting block is minimal. The effects of BBG on recovery after a 10-s prepulse were very dramatic. In control, recovery had a biphasic time course, with rapid recovery of approximately 75% of the current over the first 50 to 100 ms followed by a much slower phase of recovery that continued up to 6 s. If the total recovery in control was fit by the sum of two exponentials, the faster phase had an average time constant of 6 ± 2 ms and made up 54 ± 2% of the total recovery, whereas the slower phase had an average time constant of 300 ± 5 ms and made up 46 ± 2% (n = 4) of the total recovery. However, fits with two exponentials were not very good, and the slower phase of recovery clearly had multiple components, including components much slower than a second. Fitting the recovery from 1 to 6 s yielded a much slower time constant (2.8 ± 0.3 s, making up 7 ± 1% of the total recovery). The presence of slow components in recovery after long depolarizations to 0 mV suggests that a substantial fraction of channels enter a “slow” inactivated state from which recovery is much slower than for the conventional inactivated state reached with brief depolarizations. Such a component of slow inactivation is seen for most, if not all, sodium channels (Rudy, 1978; Vilin and Ruben, 2001; Goldin, 2003; Ulbricht, 2005) and has been described previously for sodium channels in N1E-115 cells (Errington et al., 2008).

In the presence of BBG, recovery after a 10-s depolarization to 0 mV was dramatically slowed. Almost all of the recovery occurred with slow kinetics. The fraction of current that had recovered after 100 ms at −120 mV was reduced from 73 ± 3% in control to 16 ± 3% with 3 μM BBG, 9 ± 3% with 30 μM BBG, and 5 ± 3% with 100 μM BBG (n = 4 for all). The slowing of recovery can also be quantified by comparing the time for half-recovery, which was 24 ± 6 ms in control, 854 ± 154 ms in 3 μM BBG, 1025 ± 97 ms in 30 μM BBG, and 1066 ± 150 ms in 100 μM BBG. If the recovery from 1 to 6 s was fit with an exponential, the time constant of this component slowed from 2.8 ± 0.3 s (accounting for 7 ± 1% of the total recovery) in control to 6.3 ± 0.2 s (54 ± 2% of the total) with 3 μM BBG, 6.6 ± 0.3 s (59 ± 2% of the total) with 30 μM BBG, and 5.8 ± 0.8 s (56 ± 5% of the total) with 100 μM BBG. Thus, the occupancy of the most slowly recovering states was already nearly saturated with 3 μM BBG and showed no change between 30 and 100 μM BBG. The powerful effect of even 3 μM BBG to put the great majority of channels in slowly recovering states after 10-s pulses to 0 mV suggests that BBG binds tightly to a state reached during long depolarizations, from which recovery is slow. In addition, when bound by BBG, such channels recover even more slowly (τ ~ 6 s) than the slowest component of normal recovery from slow inactivation (τ ~ 3 s).

Voltage Dependence of Slow Inactivation. The anti-epileptic agent lacosamide was proposed to inhibit sodium channel activity by affecting slow inactivation without affecting fast inactivation (Errington et al., 2008; Sheets et al., 2008; Grover et al., 2010; Kordí et al., 2010). BBG also showed significant effects on slow inactivation.

**Figure 2.** Use-dependent block by BBG. Sodium current was elicited by 20-ms depolarizations from −80 to 0 mV. After a period of slow stimulation (every 20 s), the frequency was abruptly increased to 3-Hz train. The protocol was run in control conditions and then in 3 μM BBG, which reduced the current elicited by slow stimulation from 3.0 to 1.3 nA. Peak sodium current was normalized with reference to the current with slow stimulation in each condition.

**Figure 3.** The voltage dependence of activation was not affected by BBG. A, sodium currents were elicited by a series of voltage steps from a holding potential of −80 mV to test voltages varying from −75 to 0 mV in the absence or presence of 3 μM BBG. B, current-voltage relationship for peak sodium current as a function of test pulse (different cell than A). C, conductance-voltage relationship in the absence (○) or presence (●) of BBG, calculated as $G_{Na} = I_{Na}/(V - V_{rev})$, where $G_{Na}$ is conductance, $I_{Na}$ is current (measured at the peak), and $V_{rev}$ is the reversal potential for sodium channel current (taken as +60 mV). Data were normalized to the maximum peak conductance and fit by the Boltzmann equation $1/(1 + \exp(- (V - V_{k})/k))$, where $V_{k}$ is the voltage of half-maximal activation, $V$ is test potential, and $k$ is the slope factor. Control, $V_{k} = −24.7$ mV, $k = 3.7$ mV; BBG, $V_{k} = −24.4$ mV, $k = 4.2$ mV.
We explored the possibility that BBG might interact with slow inactivation using pulse protocols similar to those previously used to study lacosamide (Errington et al., 2008). To evaluate the voltage-dependence with which channels enter slow inactivation, a 5-s prepulse to various voltages was followed by a test pulse to 0 mV delivered after a 100-ms recovery interval at −120 mV (Fig. 6A). This interval should allow complete recovery from fast inactivation, so that the test pulse assays channels remaining in a slow-inactivated state. In control, on average 31 ± 6% (n = 4) of the channels were in slowly recovering states after a 5-s prepulse to 0 mV (and 100 ms recovery at −120 mV). In the presence of BBG, there was a dramatic increase in the fraction of channels immobilized by a 5-s pulse to +20 mV in 3 μM BBG (P = 0.0015, n = 3) and 93 ± 4% by 100 μM BBG (P = 0.0001, n = 3). The midpoint also shifted more negatively in higher concentrations of BBG, with a midpoint of −80 ± 2 mV in 30 μM BBG (n = 3; P = 0.0036) and −90 ± 3 mV in 100 μM BBG (n = 3; P = 0.0007).

In principle, the apparent enhancement by BBG of slow-inactivated channels in the experiments of Figs. 5B and 6A could originate from BBG binding to fast-inactivated states, if recovery from BBG-bound fast-inactivated states was slow (e.g., if BBG unbinding was slow). To explore whether BBG entry into slowly recovering states represents binding to fast-inactivated or slow-inactivated states, we compared the kinetics of BBG-enhanced entry into slowly recovering states at two different voltages, −50 and 0 mV. Fast inactivation is nearly complete at both voltages, but in control, there is little slow inactivation at −50 mV but substantial slow inactivation at 0 mV (Fig. 6A). Therefore a difference in BBG action would be suggestive of interaction with slow-inactivated

**Fig. 4.** The voltage-dependence of inactivation was shifted by BBG. A, voltage-dependence of inactivation determined with 1-s conditioning pulses in various concentrations of BBG. Sodium channel availability was assayed by a test step to 0 mV after a 1-s prepulse to varying voltages. Lower to higher BBG solutions were sequentially applied for 1 to 2 min, and the cell was washed with control solution for 1 to 2 min between BBG solutions. B, collected data from four cells. Data from each condition in each cell were fit individually by the Boltzmann equation 1/(1 + exp(V − V1/2)), where V1/2 is voltage of half-maximal inactivation, V is test potential, and k is the slope factor. The plotted smooth curves are drawn according to the mean V1/2 and slope factor for each condition (n = 4 for all). Control, V1/2 = −66.4 ± 1.2 mV, k = 6.2 ± 0.2; 3 μM BBG, V1/2 = −72.7 ± 1.1 mV, k = 7.3 ± 0.3; 30 μM BBG: V1/2 = −80 ± 1.1 mV, k = 8.8 ± 0.4; 100 μM BBG, V1/2 = −87 ± 0.8 mV, k = 9.3 ± 0.4 (n = 4).

**Fig. 5.** Effect of BBG on the time course of recovery from inactivation. A, inactivation was produced by a 20-ms conditioning pulse (Ic) to 0 mV and a varying time for recovery (∆t) at −80 mV was applied before a test pulse (It) to 0 mV. Relative Ic/It, after each recovery time was calculated as Ic divided by It. Points and error bars show mean ± S.E.M. for experiments in four cells, each with measurements in control and with 3 μM BBG. The time course of recovery was fit with a double exponential function: y = A1(1 − exp(−t/τf)) + A2(1 − exp(−t/τs)), where t is time, A1 and A2 are the coefficients for the fast and slow exponentials, and τf and τs are the fast and slow time constants. Control: τf/mean 4.9 ± 0.4 ms, τs/mean 57.5 ± 11.4 ms; τf/peak 7.2 ± 0.8 ms; τs/peak 94 ± 16 ms. B, Time course of recovery after a 10-s conditioning pulse to 0 mV, tested with a 20-ms test pulse to 0 mV at varying times after return of the voltage to −120 mV. Test currents were normalized to the largest current elicited by the step to 0 mV in each condition.
states. Figure 6B shows the results of this experiment. The time course with which channels enter slowly recovering states at −50 mV was compared with that at 0 mV, both in control and in the presence of BBG. A step to either −50 or 0 mV varying in length from 1 to 16 s was given from a holding potential of −120 mV. A 100-ms interval at −120 mV then allowed for recovery of fast-inactivated channels, and the fraction of channels remaining in slowly recovering states was assayed by a pulse to 0 mV. Solid curves, best fits of single exponential functions decaying to a steady state. At 30/18554 or 0 mV varying in length from 1 to 16 s was given from a holding potential of −120 mV. A 100-ms interval at −120 mV then allowed for recovery of fast-inactivated channels, and the fraction of channels remaining in slowly recovering states was assayed by a pulse to 0 mV. In control, only a small fraction of channels entered slow inactivation at 0 mV (on average, 42 ± 3% after 16 s at −50 mV). A larger fraction of channels entered slow inactivation at 0 mV (on average, 58 ± 3% after 16 s at 0 mV). Entry into the slow-inactivated state was slow even at 0 mV, occurring with an average time constant of 10 ± 2 s. In the presence of BBG, a much larger fraction of channels became slowly recovering at both −50 and 0 mV, and entry into slowly recovering states was faster. With 3 μM BBG, 70 ± 4% of channels were in slowly recovering states after 16 s at −50 mV, and the time constant of entry was of 6.8 ± 1.3 s at −50 mV. With 3 μM BBG at 0 mV, development of slow-inactivation was much more complete (88 ± 3% of channels after 16 s) and also much faster (time constant of 1.7 ± 0.2 s). The effects of 30 and 100 μM BBG were more profound at both conditioning voltages but showed less dramatic differences between the two voltages. With 30 μM BBG, slow inactivation developed with a time constant of 1.4 ± 0.2 s at −50 mV (to 80 ± 6% completion) and with a time constant of 0.8 ± 0.4 s at 0 mV (to 90 ± 0% completion). Development of slow inactivation with 100 μM BBG was somewhat faster and more complete: a time constant of 0.9 ± 0.06 s at −50 mV (to 88 ± 3% completion) and a time constant of 0.6 ± 0.04 s at 0 mV (to 100 ± 4% completion). The time constants give an estimate of the speed of development of the fraction of slowly recovering channels, but it should be noted that the development of slow inactivation with 30 and 100 μM BBG was actually biphasic and imperfectly approximated by single exponential fits.

Model for BBG Binding to Resting and Inactivated States. We tested several different kinetic models for BBG interaction with various gating states of the sodium channel.

To account for the experimental data with different BBG concentrations, we found that it was necessary to assume that BBG binds to both fast-inactivated states and slow-inactivated states, with much higher-affinity binding to slow-

![Fig. 6. BBG enhancement of slowly recovering channels. A. slow inactivation was measured by applying a 5-s depolarization to varying voltages (from a steady holding potential of −120 mV), returning to −120 mV for 100 ms to allow recovery from fast inactivation, and delivering a test step to 0 mV. Test currents were normalized to the maximal test current elicited in each condition (after a conditioning pulse to −140 mV). ○, control; ●, 3 μM BBG; □, 30 μM BBG; ▲, 100 μM BBG. Data are fit by a modified Boltzmann function: \( I_{\text{max}} = (1 - I_{\text{remn}})^{(1 + \exp((V - V_{\text{h}})/k))} + I_{\text{remn}} \). Control: \( V_{\text{h}} = -34 \text{ mV}, k = 24 \text{ mV}, I_{\text{remn}} = 0.76, 3 \text{ μM BBG}: V_{\text{h}} = -58 \text{ mV}, k = 16 \text{ mV}, I_{\text{remn}} = 0.13, 30 \text{ μM BBG}: V_{\text{h}} = -84 \text{ mV}, k = 14 \text{ mV}, I_{\text{remn}} = 0.08, 100 \text{ μM BBG}: V_{\text{h}} = -95 \text{ mV}, k = 13 \text{ mV}, I_{\text{remn}} = 0.03. \) B, time course of entry into slowly recovering states at −50 mV (left) and 0 mV (right). A step to either −50 or 0 mV varying in length from 1 to 16 s was given from a holding potential of −120 mV. A 100-ms interval at −120 mV then allowed for recovery of fast-inactivated states, and the fraction of channels remaining in slowly recovering states was assayed by a pulse to 0 mV. Solid curves, best fits of single exponential functions decaying to a steady state. At −50 mV, Control: \( \tau = 16.7 \text{ s}, \text{steady state}, 0.8; 3 \text{ μM BBG}: \tau = 10.6 \text{ s}, \text{steady state} 0.2; 30 \text{ μM BBG}: \tau = 1.3 \text{ s}, \text{steady state} 0.2; 100 \text{ μM BBG}: \tau = 0.85 \text{ s}, \text{steady state} 0.1. \) At 0 mV, control: \( \tau = 13.6 \text{ s}, \text{steady state} 0.5; 3 \text{ μM BBG}: \tau = 1.9 \text{ s}, \text{steady state} 0.1; 30 \text{ μM BBG}: \tau = 0.71 \text{ s}, \text{steady state} 0.1; 100 \text{ μM BBG}: \tau = 0.59 \text{ s}, \text{steady state} 0.1. \)
inactivated states. Figure 7 shows a simple model with a single fast-inactivated state and a single slow-inactivated state that was able to simulate most of the experimental results. In the model, BBG is assumed to bind weakly to the noninactivated resting state of the channel \(K_d = 170 \, \mu M\), more tightly to the fast-inactivated state \(K_d = 5 \, \mu M\), and even more tightly to a slow-inactivated state \(K_d = 0.2 \, \mu M\). The unbinding rate of BBG from both fast-inactivated and slow-inactivated channels is slow enough that there is little recovery in 100 ms at \(-120 \, mV\); thus, the slowly recovering fraction of channels includes the states S, S-BBG, and I-BBG. The entry of channels into these slowly recovering states during a long depolarization to 0 mV occurs mainly by way of BBG binding to the fast-inactivated state I, followed by movement from I-BBG to S-BBG. There is much less movement of channels from I to S to S-BBG, because the rate constant for I to S is quite slow (but the rate constant for I-BBG to S-BBBG is faster, in a manner consistent with preserving microscopic reversibility).

We also considered a simpler model with a single fast-inactivated state to which BBG binds and unbinds slowly, thus giving large slow phases in both development and recovery. This simpler model could give a reasonable approximation for the kinetics of recovery after long depolarizations. However, it could not explain the large differences in the amount of slowly recovering block after conditioning pulses to 0 mV compared with \(-50 \, mV\). Because fast inactivation is nearly complete at \(-50 \, mV\), the fraction of channels inactivated and available to bind tightly to BBG is nearly the same at \(-50\) and 0 mV, and the degree of BBG block from binding to a single fast-inactivated state is predicted to be nearly the same at \(-50\) and 0 mV. In contrast, in the experimental data, block by 3 \, \mu M BBG is much more profound at 0 than at \(-50\) mV. This is explained by the model that includes the slow-

![Fig. 7. Kinetic model for BBG interaction with sodium channels. A, model. BBG is hypothesized to bind weakly (with 1:1 stoichiometry) to the resting closed state R, more tightly to the fast-inactivated state I, and more tightly yet to the slow-inactivated state S. For BBG binding and unbinding to R, the on-rate \((konR)\) was 0.000118 ms\(^{-1}\), \mu M\(^{-1}\), and off-rate \((koffR)\) was 0.02 ms\(^{-1}\). For BBG binding and unbinding to I, \(konI = 0.0001 \, ms^{-1} \cdot \mu M^{-1}\), and \(koffI = 0.0005 \, ms^{-1}\). For BBG binding and unbinding to S, \(konS = 0.001 \, ms^{-1} \cdot \mu M^{-1}\), and \(koffS = 0.0002 \, ms^{-1}\). Channels moved between R and I with a forward rate constant given by \(1/(1 + exp(-(V + 50)/80)) \, ms^{-1}\) and a back rate constant of 0.18/(1 + exp(-(V + 60)/80)) \, ms\(^{-1}\) and channels moved between I and S with a forward rate constant of 0.0001/(1 + exp(-(V + 25)/16)) \, ms\(^{-1}\) and back rate constant of 0.0008/(1 + exp(-(V + 25)/16)) \, ms\(^{-1}\), where \(V\) is voltage. To preserve microscopic reversibility, the rate constant for movement from I-BBG to R-BBG was multiplied by a factor of \((koffI/koffR)\) \times \((konR/konI)\) relative to that for I to R and the rate constant for movement from I-BBG to S-BBG was multiplied by a factor of \((konS/konR)\) \times \((koffI/koffS)\) relative to that for I to S. The model was implemented in IgorPro (Wavemetrics, Lake Oswego, OR) using fourth-order Runge-Kutta integration with a 200-\mu s step size. B, predictions of model for sodium channel availability (fraction of channels in state R) after 1-s conditioning pulses. As for experimental data, availability in each condition is normalized to the maximal availability after a prepulse to \(-120 \, mV\). Solid lines show fits of Boltzmann functions with the indicated midpoints. C, predictions of model for recovery of available channels at \(-120 \, mV\) after a 10-s conditioning pulse to 0 mV, according to the protocol in Fig. 5B. Availability in each concentration of BBG is normalized to the steady-state availability at \(-120 \, mV\). D, predictions of model for entry into slowly recovering states during 5-s depolarizations to a range of voltages. The x-axis plots relative fraction of channels in either state R or state I (which would be available after 100 ms recovery at \(-120 \, mV\), as in Fig. 6A). Normalization is to the maximal fraction in R or I in each condition, at \(-120 \, mV\). E, predictions of model for kinetics of entry into slowly recovering states during conditioning pulses to either \(-50\) (left) or 0 mV (right). Y axes plot relative fraction of channels in either state R or state I, and normalization is to the maximal fraction in R or I in each condition.
inactivated state, because at 0 mV a greater fraction of channels is in the slow-inactivated state than at −50 mV. As these slow-inactivated channels bind BBG with high affinity, block is more profound at 0 than at −50 mV.

The model did not match the experimental data perfectly. Most significantly, the model did not produce as large a difference as was present experimentally in the kinetics of development of block by 3 μM BBG with a conditioning prepulse to 0 mV compared with −50 mV. The model of a single fast-inactivated state and a single slow-inactivated state is highly simplified compared with the actual behavior of sodium channels, which have multiple fast-inactivated states reached from different closed states (Kuo and Bean, 1994a) and very likely multiple slow-inactivated states as well (Karoly et al., 2010). In addition, for simplicity, we connected the slow-inactivated state sequentially to the fast-inactivated state, so that channels are in one or the other but not both. In fact, however, the fast-inactivation gate can move independently of whether channels are slow-inactivated (Vedantham and Cannon, 1998), which would give considerably more complex models (Vedantham and Cannon, 1998; Karoly et al., 2010). Models with additional fast- or slow-inactivated states might better predict the much faster kinetics of BBG action during conditioning pulses to 0 mV compared with −50 mV.

**Brilliant Blue FCF Has Little Effect on Sodium Channels.** We next considered the effects on sodium channels of the structurally related dye Brilliant Blue FCF. Although BBG is a derivative of Brilliant Blue FCF, the effects of Brilliant Blue FCF were far smaller than those of BBG. Figure 8 shows the effects of Brilliant Blue FCF applied at 30 μM, 10 times the standard concentration of BBG that we used for experiments with the same voltage protocols. The effects of 30 μM Brilliant Blue FCF were far smaller than 3 μM BBG. At 30 μM, Brilliant Blue FCF had only very little effect on peak sodium current (Fig. 8A). There was also only a very small effect on the voltage-dependence of fast inactivation, with shift of 2 mV with 30 μM Brilliant Blue FCF [control: $V_{h} = −66 \text{ mV}, k = 6.6 \pm 0.13$; Brilliant Blue FCF: $V_{h} = −68.4 \text{ mV} \pm 1.1, k = 6.8 \pm 0.3$ ($n = 3$); $P = 0.05$ compared with 30 μM BBG: $V_{h} = −80 \pm 1.1 \text{ mV}, k = 8.8 \pm 0.4$). Figure 8 shows the effects of Brilliant Blue FCF applied at 30 μM Brilliant Blue FCF ([control: $V_{h} = −66 \text{ mV}, k = 6.6 \pm 0.13$; Brilliant Blue FCF: $V_{h} = −68.4 \text{ mV} \pm 1.1, k = 6.8 \pm 0.3$ ($n = 3$); $P = 0.05$ compared with 30 μM BBG: $V_{h} = −80 \pm 1.1 \text{ mV}, k = 8.8 \pm 0.4$). Recovery from slow inactivation was measured by a series of brief (20 ms) test pulses to 0 mV after a long 5-s conditioning pulse to −20 mV followed by return to −80 mV for variable times. Control: $\tau_{fast} = 6.3 \pm 0.7 \text{ ms}; \tau_{slow} = 0.7 \pm 0.1 \text{ s};$ slow fraction = 28 ±%

![Fig. 8](image_url)
for $V_h$, $P = 0.5$ for $k$), much less than the 14-mV shift seen with 30 µM BBG. In addition, Brilliant Blue FCF had little effect on the magnitude or kinetics of slow inactivation. The fraction of channels available after a 5-s prepulse to −10 mV (and a 1-s recovery at −80 mV) was 72 ± 3% in control and decreased only slightly in 30 µM Brilliant Blue FCF, to 67 ± 2% (Fig. 8C; $P = 0.183, n = 3$). By comparison, with the same voltage protocol, 3 µM BBG produced a change from 70 ± 3% available in control to 36 ± 4% in 3 µM BBG ($P = 0.0001, n = 4$). In addition, the kinetics of recovery from slow inactivation were little affected by 30 µM Brilliant Blue FCF (Fig. 8D).

**Discussion**

We found that BBG inhibits voltage-gated sodium channels at low micromolar concentrations, with an IC$_{50}$ of approximately 2 µM when applied at −60 mV, a typical neuronal resting potential. The most dramatic effect of BBG was to promote the entry of sodium channels into inactivated or drug-bound states from which recovery is slow. BBG at 3 µM enhanced the fraction of channels that recovered slowly after a 16-s depolarization to −50 mV by more than 4-fold, from 15 to 70%.

We could model the effects of BBG reasonably well by assuming a moderately high-affinity binding to a fast-inactivated state ($K_d = 5$ µM) and very high-affinity binding to a slow-inactivated state ($K_d = 0.2$ µM). As noted by Karoly et al. (2010), it is difficult to distinguish between models in which drugs bind with high affinity to slow-inactivated states and models in which drugs bind only to fast-inactivated states, but with slow kinetics. Our model includes binding to both fast-inactivated channels and slow-inactivated channels, and both seemed to be required for adequate modeling of the experimental results. With binding exclusively to slow-inactivated channels, it was impossible to model the fact that development of slowly recovering block at 0 mV is so much faster with BBG ($\tau - 2$ s with 3 µM BBG and 0.8 s with 30 µM BBG) than development of normal slow inactivation ($\tau - 10$ s), because if drug binds only to slow-inactivated channels, entry of channels into the slow-inactivated state is rate-limiting. In addition, it was impossible to produce the large shifts in inactivation measured with 1-s conditioning pulses if BBG binding was exclusive to slow-inactivated states, because entry and recovery from slow-inactivated states is so slow.

Models in which BBG binds (and unbinds) exclusively to fast-inactivated channels with relatively slow kinetics were much better able to mimic the experimental results, including the shifts in 1-s inactivation curves and the concentration-dependent development of slow-recovering channels. In addition, as noted by Karoly et al. (2010), models in which BBG binding was exclusive to the fast-inactivated state could predict the concentration-dependent shift in the apparent voltage-dependence of slow inactivation (Fig. 6A), because drug-bound fast-inactivated channels recover slowly and can mimic enhanced slow inactivation. However, models in which BBG binds exclusively to fast-inactivated channels failed in two predictions. First, a binding affinity to fast-inactivated channels (~5 µM) that accounted for the degree of shift in 1-s inactivation curves predicted much too little effect of 3 µM BBG on the fraction of channels recovering slowly after 10 s at 0 mV (Fig. 5B). Second, exclusive binding to fast-inactivated channels predicted nearly identical time course of block at −50 and 0 mV, because fast inactivation is nearly complete at both voltages. This is very different from the experimental results (Fig. 7). The much more dramatic effects of BBG at 0 mV compared with −50 mV can be explained by additional, tighter binding to slow-inactivated channels, because slow inactivation is much more pronounced at 0 mV compared with −50 mV. However, even the model with BBG binding to both fast- and slow-inactivated states in Fig. 7 failed to account quantitatively for the degree to which BBG action at 0 mV is faster than at −50 mV.

The hypothesis that BBG binds to slow- as well as fast-inactivated states can account for the observation that the BBG-induced shift in the midpoint of inactivation determined with 1-s pulses is accompanied by an increase in the slope factor (Fig. 4). This effect is not explained by models with a single inactivated state, which predict a parallel shift of the inactivation curve with no change in slope (Bean et al., 1983)—as seen experimentally with lidocaine (Bean et al., 1983), phenytoin (Kuo and Bean, 1994b), carbamazepine (Kuo, 1998), and lamotrigine (Kuo, 1998). Because the interaction of BBG with slow-inactivated states is not in steady state during 1-s conditioning pulses, progressive recovery from slowly recovering states at increasingly negative voltages produces a more shallow curve.

The specific affinities of BBG binding to fast- and slow-inactivated states predicted by the model depend on its details, but the experimental results leave no doubt that binding of BBG to combined fast- and slow-inactivated states must occur with high enough affinity that binding is nearly saturated by 3 µM BBG, which produced nearly saturating effects on recovery after 10-s depolarizations (Fig. 5B). Thus, the $K_d$ for binding to inactivated channels must be at least as low as ~0.5 µM. It is noteworthy that this is much tighter binding to inactivated channels than for many other well studied sodium channel blockers, including lidocaine (10 µM; Bean et al., 1983), lamotrigine (9 µM; Kuo and Lu, 1997), phenytoin (6 µM; Kuo and Bean, 1994b), and carbamazepine (25 µM; Kuo et al., 1997).

The promotion of slow recovery after long depolarizations by BBG is similar to the effects of lacosamide, which was proposed to have a selective interaction with slow inactivation (Errington et al., 2008). However, the effects of BBG were much more potent, with 3 µM BBG producing similar effects on slow recovery as 100 µM lacosamide (Errington et al., 2008). Unlike lacosamide, which produced no shift in inactivation studied with 500-ms conditioning steps (Errington et al., 2008), BBG produced large shifts (>20 mV) in inactivation studied with 1-s depolarizations (Fig. 4). This difference is consistent with binding of BBG to both fast-inactivated and slow-inactivated channels but lacosamide binding exclusively to slow-inactivated channels. However, it is difficult to rule out the possibility that lacosamide also binds to fast-inactivated states but with slower kinetics than BBG (Karoly et al., 2010).

Fast inactivation involves binding of a region of the III to IV intracellular linker to the intracellular pore region (West et al., 1992) whereas slow inactivation is a distinct mechanistic process that can occur in parallel with fast inactivation (Vedantham and Cannon, 1998) and may involve conformational changes of the outer pore region of the channel (Struyk and Cannon, 2002; Goldin, 2003; Xiong et al., 2003). There-
fore, high-affinity binding of BBG to slow-inactivated states may occur to an external binding site distinct from that accessed by drugs such as lidocaine, phenytoin, and carbamazepine, generally believed to bind to an internal region of the pore lumen (Ragsdale et al., 1996; Yarow-Yarovsky et al., 2001; but see Yang and Kuo, 2002; Lipkind and Fozzard, 2010).

BBG is a derivative of FD&C blue dye 1 (brilliant blue FCF), which is a commonly used food additive and is generally regarded as having little toxicity (Borzellino et al., 1990; Remy et al., 2008). Our results show that in contrast to BBG, brilliant blue FCF had very little effect on sodium channels even when applied at 10-fold higher concentrations. This is reassuring given the wide-spread ingestion of brilliant blue FCF.

BBG administration potently inhibits amyloid β-induced neuronal loss (Ryu and McLarson, 2008) and attenuates the motor coordination deficit in mouse models of mice with Huntington’s disease (Diaz-Hernandez et al., 2009). Peng and colleagues have demonstrated that BBG improves recovery after spinal cord injury. In their study, rats receiving 10 or 50 mg/kg i.v. BBG had average BBG concentrations of 9.94 ± 8.32 or 43.59 ± 14.64 μM within spinal cord tissue. These are well above the IC_{50} of 2 μM for blocking sodium channels, suggesting that the treatments may effectively inhibit sodium channels in the injured spinal cord tissue in addition to more potent inhibition of P2X7 receptors (Jiang et al., 2000).

Sodium channel blockers are of current interest for the treatment of neuropathic pain (Waxman et al., 1999; Finnerup et al., 2002; Wood et al., 2004; Cummins et al., 2007). The treatment of neuropathic pain (Waxman et al., 1999; Finne- rup et al., 2000). The lack of effect by the structurally related dye brilliant blue FCF offers the future possibility of determining the blue FCF. Energetic given the wide-spread ingestion of brilliant blue FCF.

Fast- and slow-inactivated states, and BBG acts with higher BBG inhibition seems to involve high-affinity binding to both BBG is a derivative of FD&C blue dye 1 (brilliant blue FCF), which is a commonly used food additive and is generally regarded as having little toxicity (Borzellino et al., 1990; Remy et al., 2008). Our results show that in contrast to BBG, brilliant blue FCF had very little effect on sodium channels even when applied at 10-fold higher concentrations. This is reassuring given the wide-spread ingestion of brilliant blue FCF.

BBG administration potently inhibits amyloid β-induced neuronal loss (Ryu and McLarson, 2008) and attenuates the motor coordination deficit in mouse models of mice with Huntington’s disease (Diaz-Hernandez et al., 2009). Peng and colleagues have demonstrated that BBG improves recovery after spinal cord injury. In their study, rats receiving 10 or 50 mg/kg i.v. BBG had average BBG concentrations of 9.94 ± 8.32 or 43.59 ± 14.64 μM within spinal cord tissue. These are well above the IC_{50} of 2 μM for blocking sodium channels, suggesting that the treatments may effectively inhibit sodium channels in the injured spinal cord tissue in addition to more potent inhibition of P2X7 receptors (Jiang et al., 2000).

Sodium channel blockers are of current interest for the treatment of neuropathic pain (Waxman et al., 1999; Finnerup et al., 2002; Wood et al., 2004; Cummins et al., 2007). The treatment of neuropathic pain (Waxman et al., 1999; Finnerup et al., 2000). The lack of effect by the structurally related dye brilliant blue FCF offers the future possibility of determining the blue FCF. Energetic given the wide-spread ingestion of brilliant blue FCF.

Fast- and slow-inactivated states, and BBG acts with higher BBG inhibition seems to involve high-affinity binding to both BBG is a derivative of FD&C blue dye 1 (brilliant blue FCF), which is a commonly used food additive and is generally regarded as having little toxicity (Borzellino et al., 1990; Remy et al., 2008). Our results show that in contrast to BBG, brilliant blue FCF had very little effect on sodium channels even when applied at 10-fold higher concentrations. This is reassuring given the wide-spread ingestion of brilliant blue FCF.

BBG administration potently inhibits amyloid β-induced neuronal loss (Ryu and McLarson, 2008) and attenuates the motor coordination deficit in mouse models of mice with Huntington’s disease (Diaz-Hernandez et al., 2009). Peng and colleagues have demonstrated that BBG improves recovery after spinal cord injury. In their study, rats receiving 10 or 50 mg/kg i.v. BBG had average BBG concentrations of 9.94 ± 8.32 or 43.59 ± 14.64 μM within spinal cord tissue. These are well above the IC_{50} of 2 μM for blocking sodium channels, suggesting that the treatments may effectively inhibit sodium channels in the injured spinal cord tissue in addition to more potent inhibition of P2X7 receptors (Jiang et al., 2000).

Sodium channel blockers are of current interest for the treatment of neuropathic pain (Waxman et al., 1999; Finnerup et al., 2002; Wood et al., 2004; Cummins et al., 2007). The treatment of neuropathic pain (Waxman et al., 1999; Finnerup et al., 2000). The lack of effect by the structurally related dye brilliant blue FCF offers the future possibility of determining the blue FCF. Energetic given the wide-spread ingestion of brilliant blue FCF.

Fast- and slow-inactivated states, and BBG acts with higher BBG inhibition seems to involve high-affinity binding to both BBG is a derivative of FD&C blue dye 1 (brilliant blue FCF), which is a commonly used food additive and is generally regarded as having little toxicity (Borzellino et al., 1990; Remy et al., 2008). Our results show that in contrast to BBG, brilliant blue FCF had very little effect on sodium channels even when applied at 10-fold higher concentrations. This is reassuring given the wide-spread ingestion of brilliant blue FCF.

BBG administration potently inhibits amyloid β-induced neuronal loss (Ryu and McLarson, 2008) and attenuates the motor coordination deficit in mouse models of mice with Huntington’s disease (Diaz-Hernandez et al., 2009). Peng and colleagues have demonstrated that BBG improves recovery after spinal cord injury. In their study, rats receiving 10 or 50 mg/kg i.v. BBG had average BBG concentrations of 9.94 ± 8.32 or 43.59 ± 14.64 μM within spinal cord tissue. These are well above the IC_{50} of 2 μM for blocking sodium channels, suggesting that the treatments may effectively inhibit sodium channels in the injured spinal cord tissue in addition to more potent inhibition of P2X7 receptors (Jiang et al., 2000).

Sodium channel blockers are of current interest for the treatment of neuropathic pain (Waxman et al., 1999; Finnerup et al., 2002; Wood et al., 2004; Cummins et al., 2007). The treatment of neuropathic pain (Waxman et al., 1999; Finnerup et al., 2000). The lack of effect by the structurally related dye brilliant blue FCF offers the future possibility of determining the blue FCF. Energetic given the wide-spread ingestion of brilliant blue FCF.

Fast- and slow-inactivated states, and BBG acts with higher BBG inhibition seems to involve high-affinity binding to both BBG is a derivative of FD&C blue dye 1 (brilliant blue FCF), which is a commonly used food additive and is generally regarded as having little toxicity (Borzellino et al., 1990; Remy et al., 2008). Our results show that in contrast to BBG, brilliant blue FCF had very little effect on sodium channels even when applied at 10-fold higher concentrations. This is reassuring given the wide-spread ingestion of brilliant blue FCF.

BBG administration potently inhibits amyloid β-induced neuronal loss (Ryu and McLarson, 2008) and attenuates the motor coordination deficit in mouse models of mice with Huntington’s disease (Diaz-Hernandez et al., 2009). Peng and colleagues have demonstrated that BBG improves recovery after spinal cord injury. In their study, rats receiving 10 or 50 mg/kg i.v. BBG had average BBG concentrations of 9.94 ± 8.32 or 43.59 ± 14.64 μM within spinal cord tissue. These are well above the IC_{50} of 2 μM for blocking sodium channels, suggesting that the treatments may effectively inhibit sodium channels in the injured spinal cord tissue in addition to more potent inhibition of P2X7 receptors (Jiang et al., 2000).

Sodium channel blockers are of current interest for the treatment of neuropathic pain (Waxman et al., 1999; Finnerup et al., 2002; Wood et al., 2004; Cummins et al., 2007). The treatment of neuropathic pain (Waxman et al., 1999; Finnerup et al., 2000). The lack of effect by the structurally related dye brilliant blue FCF offers the future possibility of determining the blue FCF. Energetic given the wide-spread ingestion of brilliant blue FCF.

Fast- and slow-inactivated states, and BBG acts with higher BBG inhibition seems to involve high-affinity binding to both BBG is a derivative of FD&C blue dye 1 (brilliant blue FCF), which is a commonly used food additive and is generally regarded as having little toxicity (Borzellino et al., 1990; Remy et al., 2008). Our results show that in contrast to BBG, brilliant blue FCF had very little effect on sodium channels even when applied at 10-fold higher concentrations. This is reassuring given the wide-spread ingestion of brilliant blue FCF.

Address correspondence to: Dr. Bruce P. Bean, Department of Neurobiology, Harvard Medical School, 220 Longwood Ave, Boston, MA 02115. E-mail: bruce_bean@hms.harvard.edu